Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. User Boards ›
  4. NASDAQ DIP and RIP Message Board

Put on watch> Threshold Pharmaceuticals, In (THLD)

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 23094
Posted On: 12/07/2015 6:58:36 PM
Avatar
Posted By: fitzkarz
Put on watch> Threshold Pharmaceuticals, In (THLD)
$ 0.60 ▼-2.74 ( -82.04% )
Volume: 33,177,728

UPDATE: Threshold Pharmaceuticals' stock plunges after drug trial disappoints
7 hours 56 minutes ago - DJNF
By Tomi Kilgore, MarketWatch

Stock hits 7-year low, as volume spikes to 24 times the full-day average in the first 90 minutes of trade

Threshold Pharmaceuticals Inc.'s stock plunged in very active trade to a seven-year low Monday, after two late-stage trials of its investigational cancer treatment failed to meet their primary endpoints.

The stock (THLD) slid as much as 85% early in the session to an intraday low of 51 cents, which was the lowest price seen since Dec. 24, 2008. Volume in the first 90 minutes of trade was 19.5 million shares, or about 24 times the full-day average of about 803,495 shares, according to FactSet.

(https://w.graphiq.com/w/ke7sVtn644Z)

The company said early Monday that one Phase 3 study of evofosfamide, in patients with previously untreated metastatic pancreatic cancer, did not demonstrate a statistically-significant improvement in overall survival when compared with a placebo. Another Phase 3 trial didn't show a statistically-significant improvement in overall survival when compared with doxorubicin, a medication used in chemotherapy.

"We are surprised and disappointed that these studies did not show that evofosfamide could extend the lives of patients with these two difficult-to-treat diseases," said Chief Executive Barry Selick. "While we believe there remains substantial data to support the role of hypoxia in cancer treatment resistance, we are deeply frustrated with our inability in these trials to impact that in a meaningful way.

Prior to Monday's selloff, the Threshold's stock had gained 5% year to date, while the S&P 500 had tacked on 1.6%.

-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

December 07, 2015 11:04 ET (16:04 GMT)

Copyright (c) 2015 Dow Jones & Company, Inc.


(0)
(0)




I'm in it to win it!

NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.

I was born with it, I'm truly blessed!


Alway's searching for winners'
937206596_images.jpg




Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us